Adlai Nortye Group (ANL) vs LB Pharmaceuticals (LBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed LB Pharmaceuticals (LBRX) over the past year, gaining 796.5% versus a gain of 130.1%. LB Pharmaceuticals is the larger company by market cap ($1.22 billion vs $1.03 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | LBRX |
|---|---|---|
| Share price | $16.04 | $37.84 |
| Market cap | $1.03B | $1.22B |
| 1-day change | +3.42% | +9.33% |
| YTD return | +992.25% | +55.48% |
| 1-year return | +796.53% | +130.12% |
| P/E ratio (TTM) | — | 378.40 |
| EPS (TTM) | $-0.66 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $50.16 |
| 52-week low | $0.879 | $14.32 |
| Distance from 52-week high | -7.01% | -24.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +83.92% | +51.43% |
| Average volume | 187.30K | 344.34K |
| Shares outstanding | 58.73M | 32.26M |
| Employees | 109 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed LBRX by 666.4 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
ANL vs LBRX FAQ
Which is bigger, Adlai Nortye Group or LB Pharmaceuticals?
LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.22B compared with $1.03B for Adlai Nortye Group (ANL).
Which stock has performed better over the past year, ANL or LBRX?
ANL returned +796.53% over the past 12 months, compared with +130.12% for LBRX (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and LB Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.